A former senior executive at BTG, LLC, Kenneth “Ken” Pugh is an independent consultant currently serving as a board member of Prohibix, LLC. Residing in Chester County, PA, Kenneth Pugh played a leading role in the introduction of LC Bead Lumi in the United States while serving as vice president for commercial development in the Americas for BTG.
The April 2016 launch of LC Bead Lumi in the United States marked the first time a radiopaque embolic bead became commercially available. The product is most useful for the embolization of arteriovenous malformations and hypervascular tumors became commercially available. Embolization is a procedure where fragments, including beads and minute gelatin sponges, are utilized to block a blood vessel. It may be used to stop bleeding or stop blood flow to an abnormal section of tissue or tumor.
As LC Bead Lumi is radiopaque, it can be seen by X-ray and analyzed by doctors or interventional radiologists. More importantly, medical experts can have a real-time visual confirmation of the bead's location during the procedure. There is more control as well as a more precise evaluation of tumor treatment. Long-lasting radiopacity also assists in follow-up management which increases the likelihood of an improved patient outcome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.